Myasthenia Gravis Panel 2
Order Name
ACETY BBM
Test Number: 5500250
Revision Date 01/01/2024
Test Number: 5500250
Revision Date 01/01/2024
Test Name | Methodology | LOINC Code |
---|---|---|
Acetylcholine Receptor Binding Antibody
|
See Test Notes | 11034-6 |
Acetylcholine Receptor Blocking Antibody
|
See Test Notes | 11561-8 |
Acetylcholine Receptor Modulating Antibody
|
Flow cytometry | 30192-9 |
SPECIMEN REQUIREMENTS | ||||
---|---|---|---|---|
Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
Preferred | 2 mL (1.5) | Serum | Clot Activator SST | Refrigerated |
Alternate 1 | 2 mL (1.5) | Serum | Clot Activator (Red Top, No-Gel) | Refrigerated |
Instructions | Separate serum from cells ASAP or within 2 hours of collection Unacceptable Conditions: Contaminated, hemolyzed, or severely lipemic specimens. Stability After separation from cells: Ambient: 2 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) |
GENERAL INFORMATION | |
---|---|
Testing Schedule | Sun-Sat |
Expected TAT | 4-6 Days |
Clinical Use | Myastenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myastenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody. |
CPT Code(s) | 86041, 86042, 86043 |
Lab Section | Reference Lab |